Research Use Only. The information presented here is for scientific and educational purposes. These compounds are not intended for human consumption, self-administration, or therapeutic use.
Introduction
The CJC-1295 + Ipamorelin blend is one of the most frequently studied growth-hormone-secretagogue combinations in the preclinical peptide literature. It pairs CJC-1295, a synthetic analog of growth hormone-releasing hormone (GHRH), with Ipamorelin, a selective pentapeptide growth hormone secretagogue. The two are co-lyophilized and studied together because they act on distinct but complementary receptors of the growth hormone axis.
This overview summarizes what each component is, why researchers investigate them in combination, and the laboratory considerations relevant to the blend. All material is for research use only.
The Two Components
CJC-1295, a GHRH analog
CJC-1295 (a modified GRF 1-29 sequence) is studied for its interaction with the GHRH receptor on pituitary somatotrophs. As a GHRH analog, it is investigated in research on the secretagogue regulation of growth hormone release and on extended-half-life GHRH-analog pharmacology. See our CJC-1295 research overview.
Ipamorelin, a selective GH secretagogue
Ipamorelin is a synthetic pentapeptide studied for selective agonism at the growth hormone secretagogue receptor (GHS-R1a, the ghrelin receptor), with minimal off-target activity reported in preclinical models. See our Ipamorelin research overview.
Why They’re Studied Together
The combination rationale rests on complementary receptor engagement: CJC-1295 acts at the GHRH receptor, while Ipamorelin acts at the GHS-R1a (ghrelin) receptor. Because these are two separate inputs into the same somatotropic (GH/IGF-1) axis, researchers study the pair to investigate how the two secretagogue pathways interact when engaged together, compared with either compound alone.
As with any combination, the research-relevant questions are whether the two inputs produce additive, synergistic, or merely concurrent effects on the studied endpoints, questions best addressed with a design that includes single-compound arms alongside the blend. For a broader comparison of GHRH analogs, see our GHRH analog comparison.
Research Considerations
- Format: co-lyophilized powder in a fixed mass ratio of the two components.
- Reconstitution: typically bacteriostatic water for multi-use research workflows.
- Storage: store lyophilized cold and protected from light; refrigerate after reconstitution and minimize freeze-thaw cycles.
- Purity: research-grade material should carry a lot-specific Certificate of Analysis with HPLC purity and mass-spec identity confirmation for each component (see how to read a COA).
- Fixed-ratio constraint: because the components are co-lyophilized, the blend dose varies both proportionally; component-contribution studies typically use the individual peptides separately.
Frequently Asked Questions
What is the CJC-1295 + Ipamorelin blend?
A co-lyophilized research combination of CJC-1295 (a GHRH analog) and Ipamorelin (a selective GH secretagogue), studied together for their complementary action on the growth-hormone axis. For laboratory research use only.
Why are CJC-1295 and Ipamorelin combined in research?
They engage different receptors of the same axis, the GHRH receptor (CJC-1295) and the GHS-R1a ghrelin receptor (Ipamorelin), so the pair is used to study how the two secretagogue inputs behave together versus separately.
How is the blend reconstituted in research settings?
Typically with bacteriostatic water, which allows multi-use access to a single vial. Reconstituted solutions are refrigerated and used within a limited window.
What purity should the blend have?
Research-grade material should document ≥98% HPLC purity per component with mass-spec identity confirmation on a lot-specific Certificate of Analysis.
Is the blend intended for human use?
No. It is sold strictly for laboratory research use and is not intended for human or animal use of any kind.
References
- Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. PMID: 16352683.
- Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. PMID: 9849822.
